ArticleFrontiers in oncology2026

Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational study.

Tatiana Yu Kochetova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.